Last week, we saw the House Oversight Committee pass the House DRUG Bill (H.R. 6283). This bipartisan legislation would:

• Ban PBMs from charging fees based on a drug's list price, instead allowing PBMs to charge a flat fee for service; 
• Ban spread pricing, in which PBMs charge insurers more than they pay pharmacies; and
• Prohibit PBMs from steering patients to affiliated pharmacies.

Congressman Lynch also spoke on an amendment that would increase transparency and oversight of PBM practices. 

Continue this momentum and see meaningful PBM reform included in the March 8th CR package. Contact Senator Markey's and Representative Trahan's offices via email or social media to encourage their support for Senate Bill 1542 and H.R. 6283.